Glucagon-Like Peptide-1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study.
GLP-1 receptor agonists keep getting attention. This time, researchers out of Korea ran a nationwide study to check if these peptides are linked to mental health disorders in adults with type 2 diabetes. They compared GLP-1 agonists with two other popular diabetes treatments: SGLT2 inhibitors and DPP-4 inhibitors. The big question: do GLP-1 peptides carry any extra risk for issues like depression, anxiety, or sleep problems?
Diabetes Obes Metab
by Kim C, Kim S, Lee DY et al.
“Glucagon-Like Peptide-1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study. Kim C(1)(2), Kim S(3)(4), Lee DY(1)(5), Han E(6), Lee YH(4)(7), You SC(3)(4). Author information: (1)Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea. (2)Center for Outcomes Research and Evaluations, Yale New Haven Hospital, New Haven, Connecticut, USA. (3)Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea. (4)Yonsei Institute for Digital Health, Yonsei University, Seoul, Republic of Korea. (5)Bongdam Forest Mental Health Clinic, Hwaseong, Republic of Korea. (6)Department of Internal Medicine, Keimyung University, School of Medicine, Daegu, Republic of Korea. (7)Department of Internal Medicine, Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Republic of Korea. AIMS: We evaluated the risk of mental health disorders among glucagon-like peptide-1 receptor agonist (GLP1RA) users compared with users of dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter-2 (SGLT2) inhibitors. MATERIALS AND METHODS: We conducted a nationwide, active-comparator new-user cohort study using the Korean claims database from 2012 to 2022. Patients aged ≥ 18 years who initiated GLP1RAs, SGLT2 inhibitors, or DPP4 inhibitors for type 2 diabetes were included. We compared the hazard ratios (HRs) and 95% confidence intervals (CIs) for depression, anxiety, sleep disorders, and suicide using the Cox proportional hazards models after propensity score matching. RESULTS: The 18 825 GLP1RA users were matched with 623 750 SGLT2 inhibitor users, and 5762 GLP1RA users with 874 902 inhibitor users. Compared with DPP4 inhibitors, GLP1RAs were not associated with increased risks of depression (HR 1.00 [95% CI, 0.83-1.20]), anxiety (0.92 [0.77-1.08]), or sleep disorder (1.14 [0.97-1.33]). In contrast, compared with SGLT2 inhibitors, GLP1RA use was associated with higher risks of depression (1.20 [1.09-1.31]) and anxiety (1.09 [1.00-1.19]). Suicidality events were rare and not observed among GLP1RA users. CONCLUSIONS: Initiation of GLP1RAs was not associated with increased risk of mental health disorders compared with DPP4 inhibitors. Differences in the risk of depression and anxiety were observed compared with SGLT2 inhibitors. These findings suggest that psychiatric safety signals may vary by active comparator and provide real-world evidence on the psychiatric safety of GLP-1-based therapies. Further studies incorporating detailed clinical data and high-risk subgroups are needed to clarify underlying mechanisms. © 2026 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.”
The team analyzed health records from over a decade, pulling data from more than 1.5 million patients. They used propensity score matching—a fancy way of leveling the playing field between groups—to make sure their comparisons were solid.
Key findings:
GLP-1 receptor agonists were not linked to higher rates of depression, anxiety, or sleep disorder compared to DPP-4 inhibitors.
Compared to SGLT2 inhibitors, GLP-1 agonists showed a slight bump in risk for depression (hazard ratio 1.20) and anxiety (hazard ratio 1.09).
Suicidality events were extremely rare. Not a single event was observed among GLP-1 agonist users.
So what does this mean for peptide research? First, not all peptides are created equal—even among anti-diabetic treatments. Second, mental health outcomes may depend on the specific comparator. GLP-1 receptor agonists hold up well against DPP-4 inhibitors, but the story gets more nuanced with SGLT2s.
Researchers want more data, especially detailed clinical info and high-risk subgroups, to really dial in on mechanisms. But for now, GLP-1 peptides look stable from a psychiatric safety angle, at least by these comparisons.
Curious about more peptide research? Check out the peptide research index for deeper dives. Real-world data like this helps move the field forward.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.